Storia in 2 fonti

AstraZeneca and Bristol-Myers: when Big Pharma isn’t big enough

Sheer mass helps when enlarged balance sheets allow for bigger bets on potential blockbuster drugs

Raccontata da

statnews.com

ft.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

ft.comStai leggendo17 h fa

AstraZeneca and Bristol-Myers: when Big Pharma isn’t big enough

Sheer mass helps when enlarged balance sheets allow for bigger bets on potential blockbuster drugs

originale

statnews.com20 h fa

Pharmalittle: We're reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more

AstraZeneca-BMS merger talks at ~$400B face skepticism (AstraZeneca down 5.5%). Amgen breach via third-party cloud vendor signals rising enterprise risk from managed infrastructure; demands IT governance review of vendor data access and compliance posture.

Leggi questa versione → originale

Timeline cronologica

lunedì 3 agosto 2026·statnews.com
Pharmalittle: We're reading about AstraZeneca-Bristol merger talks, a revised 340B plan, and more
AstraZeneca stock fell as investors balked at reports of merger talks with Bristol Myers Squibb about forming one of the world's biggest drugmakers
lunedì 3 agosto 2026·ft.com
AstraZeneca and Bristol-Myers: when Big Pharma isn’t big enough
Sheer mass helps when enlarged balance sheets allow for bigger bets on potential blockbuster drugs